4D pharma announces clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518 in combination with BAVENCIO® for the treatment of locally advanced or
4d Pharma PLC (DDDD.L) presents update on oncology program
Enrollment progressing well for both expanded Part B of MRx0518 and Keytruda® combination study, and pancreatic cancer study
4d Pharma PLC (DDDD.L) Joins MJFF-sponsored Parkinson’s study consortium
4D pharma Joins Landmark Parkinson’s Progression Markers Initiative
4d Pharma PLC (DDDD.L) Registration Statement filed with SEC
4D pharma files Registration Statement on Form F-4 with U.S. Securities and Exchange Commission
4d Pharma PLC (DDDD.L) Longevity extends Business Combination deadline
Longevity receives shareholder approval to extend business combination deadline
4d Pharma PLC (DDDD.L) Presentations on MRx0518 at SITC 2020
4D pharma announces three presentations at The Society for Immunotherapy of Cancer (SITC) Annual Meeting 2020
4d Pharma PLC (DDDD.L) Topline Results for Blautix® phase II trial
Positive trends seen in primary efficacy endpoint of the study of overall response in both IBS-C and IBS-D subgroups
4d Pharma PLC (DDDD.L) Interim Results
Interim results for the six months ended 30 June 2020
4d Pharma PLC (DDDD.L) MRx0158 Keytruda Part A clinical benefit data
4D pharma announces comprehensive clinical benefit data from Part A of combination trial of MRx0518 and Keytruda®
4d Pharma PLC (DDDD.L) COVID-19 study open for enrolment
Phase II study of MRx-4DP0004 in patients hospitalized with COVID-19 open for enrolment
4d Pharma PLC (DDDD.L) Phase II study in COVID-19
Expedited UK regulatory acceptance to commence Phase II study in COVID-19